Recruiting
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
ClinicalTrials.gov IDNCT06330012
PhaseNA
Enrollment50
SponsorSamsung Medical Center
AgeNo minimum reported
SexFEMALE
Conditions studied
HER2-positive Breast Cancer
About this study
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Interventions
- Diagnostic Test: GeoMx data analysis with clinical outcome — 1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Primary outcomes
- Spatial transcriptomic analysis (Before chemotherapy, curative surgery)
Eligibility information
Inclusion Criteria:
* HER2 positive breast cancer
* Stage IV disease
* Treated with T-Dxd
* Available FFPE samples
Exclusion Criteria:
* TNBC breast cancer
* Hormone receptor positive breast cancer
* Non-available FFPE samples
* Treated except T-Dxd
Study locations
- Ji-Yeon Kim, Seoul, 06351 South Korea
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.